This is a working overview of hGH fragment, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-10-14. Anything still debated is marked as such rather than presented as settled.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
| Property | Value | Notes |
|---|---|---|
| Common synonym | hGH fragment 176-191 | Refers to the C-terminal segment |
| Appearance | White to off-white powder | Typically supplied lyophilized |
| Solubility | Soluble in water and aqueous buffers | Confirm with technical data |
| Typical storage temperature | -20 °C for dry powder | Protect from moisture and light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
==== Small RNA ==== At first, regulatory RNA was thought to be a eukaryotic phenomenon, a part of the explanation for why so much more transcription in higher organisms was seen than had been predicted. But as soon as researchers began to look for possible RNA regulators in bacteria, they turned up there as well, termed as small RNA (sRNA). Currently, the ubiquitous nature of systems of RNA regulation of genes has been discussed as support for the RNA World theory. There are indications that the enterobacterial sRNAs are involved in various cellular processes and seem to have significant role in stress responses such as membrane stress, starvation stress, phosphosugar stress and DNA damage. Also, it has been suggested that sRNAs have been evolved to have important role in stress responses because of their kinetic properties that allow for rapid response and stabilisation of the physiological state. Bacterial small RNAs generally act via antisense pairing with mRNA to down-regulate its translation, either by affecting stability or affecting cis-binding ability. Riboswitches have also been discovered. They are cis-acting regulatory RNA sequences acting allosterically. They change shape when they bind metabolites so that they gain or lose the ability to bind chromatin to regulate expression of genes.
In 1981, Frank D. Hickingbotham (b. 1936) opened the first TCBY in Little Rock, Arkansas. TCBY began franchising the following year, and had expanded to over 100 locations by 1984. Prior to 1984, the company's name was "This Can't Be Yogurt," but a lawsuit from a competitor, I Can't Believe It's Yogurt!, forced TCBY to create a new name from its initials, eventually using "The Country's Best Yogurt". TCBY began co-branding with Taco Bell, McDonald's, Subway, and Burger King in 1995. In 1991 TCBY moved into the tallest building in Arkansas, the forty-story Simmons Tower located in downtown Little Rock, and the building was renamed The TCBY Tower until 2000 when TCBY vacated. Mrs. Fields acquired TCBY in early 2000 and became Mrs. Fields Famous Brands. The combined company relocated headquarters to Broomfield, Colorado in 2012. TCBY was also present in Honduras, Costa Rica and Nicaragua for several years, but closed all of its branches. In 2001, there were 1,777 TCBY locations across the United States. By 2011, after several waves of closings, there were 405.
=== Growth Factors === Growth Factor enhanced grafts are produced using recombinant DNA technology. They consist of either Human Growth Factors or Morphogens (Bone Morphogenic Proteins in conjunction with a carrier medium, such as collagen).
=== Letby's testimony === Letby gave evidence in May 2023. Under questioning by her defence barrister, she became tearful and said she had been made to feel incompetent but had "meant no harm." She told the court that the allegations had severely affected her mental health and left her feeling isolated from colleagues. Reporting from the trial noted that she sometimes contradicted herself, became confused about aspects of her account and grew increasingly frustrated during cross‑examination, which observers contrasted with her usual calm presentation.
=== Pharmacokinetics === Vasopressin is administered through an intravenous device, intramuscular injection or a subcutaneous injection. The duration of action depends on the mode of administration and ranges from thirty minutes to two hours. It has a half life of ten to twenty minutes. It is widely distributed throughout the body and remains in the extracellular fluid. It is degraded by the liver and excreted through the kidneys. Arginin vasopressins for use in septic shock are intended for intravenous use only.
Sources: en.wikipedia.org
==== Prostaglandin E1 (PGE1) agonists ==== Alprostadil (Caverject; Prostaglandin E1) – prostaglandin E1 (PGE1) agonist – erectile dysfunction [129] Alprostadil alfadex (alprostadil alfadex complex; alprostadil-alpha-cyclodextrin; Edex; Prostaglandin E1-α-cyclodextrin complex; Prostandin; Prostavasin; Rigidur; Sugiran; Vasaprostan; Vasoprost; Viridal) – prostaglandin E1 (PGE1) agonist – erectile dysfunction [130] Alprostadil topical (Alprox-TD; Befar; Cold Chain Vitaros; Femprox; RayVa; Room Temperature Vitaros; Virirec; Vitaros; Vytaros; WC-3036) – prostaglandin E1 (PGE1) agonist – erectile dysfunction [131]
In 2011, CLASP was appointed as the Operating Agent for the Super-efficient Equipment and Appliance Deployment (SEAD) initiative, a multilateral collaboration initiated by the Clean Energy Ministerial (CEM) and the International Partnership for Energy Efficiency Cooperation (IPEEC) to transform the global market toward higher energy efficiency. SEAD member governments include Australia, Brazil, Canada, the European Commission, France, Germany, India, Japan, Korea, Mexico, Russia, South Africa, Sweden, the United Arab Emirates, the United Kingdom, and the United States. China participates as an observer.
=== Resale status === As a result of earlier unauthorized sales to civilians, the Department of Defense requires that "U.S. Government Property, Commercial Resale is Unlawful" be printed on each case of MREs. The warning is only intended for service members, as there are no laws that forbid the resale of MREs by civilians. Although the government has attempted to discourage sellers from selling MREs, auction sites such as eBay have continued to allow auctions of the MREs because the Department of Defense has been unable to provide any regulations or laws specifically outlawing the practice. According to a spokesman for eBay, "until a law is passed saying you can't sell these things, we're not going to stop them from being sold on the site." Therefore, while MREs are not prima facie contraband, the procurement and sale of MREs by military personnel for personal profit is illegal under the Uniform Code of Military Justice Article 108. As a result, MREs found for sale outside reputable vendors often fall into a grey market where the question of how it entered civilian hands (through theft/legitimate means) and/or its quality may be unknown. An investigation conducted in 2006 on behalf of the U.S. Government Accountability Office (GAO) determined multiple instances where sellers on eBay may have improperly obtained MREs and sold them to the public for private gain. As military MREs are procured at taxpayers' expense, they are intended to be consumed by individuals from authorized organizations and activities.
When bacteria grow in anaerobic environments, the terminal electron acceptor is reduced by an enzyme called a reductase. E. coli can use fumarate reductase, nitrate reductase, nitrite reductase, DMSO reductase, or trimethylamine-N-oxide reductase, depending on the availability of these acceptors in the environment. Most terminal oxidases and reductases are inducible. They are synthesized by the organism as needed, in response to specific environmental conditions.
Jolene is a 2008 American drama film directed by Dan Ireland, based on the 2002 short story "Jolene: A Life" by E. L. Doctorow. It marked Jessica Chastain's film debut. It premiered at the Seattle International Film Festival on June 13, 2008. It was later released in the United States on October 29, 2010.
Sources: en.wikipedia.org
Tyrosine hydroxylase is a tetramer of four identical subunits (homotetramer). Each subunit consists of three domains. At the carboxyl terminal of the peptide chain there's a short alpha helix domain that allows tetramerization. The central ~300 amino acids make up a catalytic core, in which all the residues necessary for catalysis are located, along with a non-covalently bound iron atom. The iron is held in place by two histidine residues and one glutamate residue, making it a non-heme, non-iron-sulfur iron-containing enzyme. The amino terminal ~150 amino acids make up a regulatory domain, thought to control access of substrates to the active site. In humans there are thought to be four different versions of this regulatory domain, and thus four versions of the enzyme, depending on alternative splicing, though none of their structures have yet been properly determined. It has been suggested that this domain might be an intrinsically unstructured protein, which has no clearly defined tertiary structure, but so far no evidence has been presented supporting this claim. It has however been shown that the domain has a low occurrence of secondary structures, which doesn't weaken suspicions of it having a disordered overall structure. As for the tetramerization and catalytic domains their structure was found with rat tyrosine hydroxylase using X-ray crystallography. This has shown how its structure is very similar to that of phenylalanine hydroxylase and tryptophan hydroxylase; together the three make up a family of homologous aromatic amino acid hydroxylases.
For instance, lichenologists long recognized species pairs where one species is fertile (has apothecia) and a very similar one is sterile but has abundant vegetative propagules such as soredia or isidia. Classical "species-pairs"—for example, fertile Parmelia saxatilis versus sorediate P. sulcata—have proven to be single species exhibiting alternative reproductive modes. DNA data have therefore prompted many merges, where differences were superficial, and still more splits, where hidden lineages emerged. Lichenologists now rely on integrative taxonomy and modern delimitation tools to resolve species limits. Current practice combines genetic, morphological, and ecological evidence when defining species. Lücking, Leavitt, and David Leslie Hawksworth (2021) proposed a "Lichen Unified Species Concept" that weighs three evidence lines: Lineage (genetic divergence), Phenotype (morphology/chemistry), and Reproduction (isolation)—the LPR framework. A robust species is one that forms a well-supported clade, shows consistent phenotypic differences from relatives, and exhibits some reproductive barrier. Complete evidence is rare; the aim is concordance among whatever data are available. The authors also framed taxonomy in terms of errors: false positives (over-splitting) and false negatives (over-lumping). Morphology alone risks false positives; a single gene alone risks false negatives.
No chromosome translocations, chimeric genes, or fusion proteins have been described in BIA-ALCL although the neoplastic cells in the disease have been described to have gene copy number variations involving gains in gene copies on the p arm of chromosome 19 and losses of gene copies in the p arms of chromosome 10 and 1. The neoplastic cells in BIA-ALCL show mutations of the STAT3 gene in 64% of cases and reports of mutations in JAK1, JAK3, DNMT3A, and TP53 genes. The development of BIA-ALCL, it has often been suggested, may be at least in part a T-cell-induced, inflammation-driven cancer response to the implant.
Uranium-235 makes up about 0.72% of natural uranium. Unlike the predominant isotope uranium-238, it is fissile, i.e., it can sustain a fission chain reaction. It is the only fissile isotope that is a primordial nuclide or found in significant quantity in nature. Uranium-235 has a half-life of 704 million years. It was discovered in 1935 by Arthur Jeffrey Dempster. Its fission cross section for slow thermal neutrons is about 584.3±1 barns. For fast neutrons it is on the order of 1 barn. At thermal energy levels, about 5 of 6 neutron absorptions result in fission and 1 of 6 result in neutron capture forming uranium-236. The fission-to-capture ratio improves for faster neutrons.
Sources: en.wikipedia.org
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.
No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.
Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.